Evidence map›Paper›PMID 35734413›Full record

ArticleFrontiers in pharmacology2022

Real-World Data and Budget Impact Analysis (BIA): Evaluation of a Targeted Next-Generation Sequencing Diagnostic Approach in Two Orthopedic Rare Diseases.

Elena Pedrini, Antonella Negro, Eugenio Di Brino, Valentina Pecoraro, Camilla Sculco, Elisabetta Abelli, Maria Gnoli, Armando Magrelli, Luca Sangiorgi, Americo Cicchetti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Elena PedriniDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Antonella NegroRegional Agency for Health and Social Care of Emilia-Romagna, Bologna, Italy.
Eugenio Di BrinoUniversità Cattolica del Sacro Cuore, Graduate School of Health Economics and Management, Rome, Italy.
Valentina PecoraroRegional Agency for Health and Social Care of Emilia-Romagna, Bologna, Italy.
Camilla SculcoSchool of Economics and Management, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Elisabetta AbelliDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Maria GnoliDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Armando MagrelliNational Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy.
Luca SangiorgiDepartment of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Americo CicchettiUniversità Cattolica del Sacro Cuore, Graduate School of Health Economics and Management, Rome, Italy.
Istituto Ortopedico Rizzoli · ITAgenzia Sanitaria e Sociale Regionale · ITUniversità Cattolica del Sacro Cuore · ITIstituto Superiore di Sanità · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Budget Impact Analysis (BIA)multiple osteochondromasNGSosteogenesis imperfectarare diseases

Identifiers

PMID35734413
PMCPMC9207266
OpenAlexW4281685089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.